Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 25;21(1):126.
doi: 10.1186/s12905-021-01262-z.

Acceptability and feasibility of the CHARISMA counseling intervention to support women's use of pre-exposure prophylaxis: results of a pilot study

Affiliations

Acceptability and feasibility of the CHARISMA counseling intervention to support women's use of pre-exposure prophylaxis: results of a pilot study

Ellen K Wilson et al. BMC Womens Health. .

Abstract

Background: Women may need or seek male partner approval to safely and consistently use oral antiretroviral pre-exposure prophylaxis (PrEP) or vaginal microbicides. We developed CHARISMA, a counseling intervention to support women's relationships and their ability to consistently use HIV prevention products.

Methods: In a pilot study with 95 female participants in Johannesburg, South Africa, lay counselors implemented CHARISMA, assessing participants' relationship(s) with their male partner(s) and barriers or facilitators to HIV prevention method use, and then providing tailored, interactive counseling. We conducted study participant surveys and clinic staff interviews to evaluate CHARISMA's feasibility and acceptability.

Results: The CHARISMA pilot study indicates that a two-session relationship counseling intervention with 6-month follow-up to support women's ability to safely and effectively use vaginal microbicides was generally acceptable and feasible. Most participants thought CHARISMA was relevant, helpful, and about the right length, and that it had a positive impact on their relationships with their partners and their product use. Staff estimated that the intervention took 1.5-2 h to implement at enrollment and 45 min to an hour for the month 1 visit. They thought that overall CHARISMA was generally feasible to implement.

Conclusions: Findings from this study suggest several lessons learned that may be relevant to others developing interventions supporting women's use of oral PrEP or vaginal microbicides. The use of lay counselors instead of nurses to deliver counseling appeared to be successful, but the counselors experienced significant stress from hearing about participants' traumatic experiences and required emotional support to avoid burnout. Although staff and participants felt that having multiple intervention sessions over time was valuable, a similar level of intensity may not be feasible in other settings. Further research is needed to determine an intervention delivery mode and follow-up period that optimally balances participant needs and clinic resources. Male engagement was a challenge, as it has been in previous studies of vaginal microbicides. Alternative strategies to reach men that do not require them to come to the clinic or rely on their female partners may be more effective.

Keywords: Evaluation; HIV prevention; Intimate partner violence; Microbicides; PrEP; South Africa.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no competing interests.

Figures

Fig. 1
Fig. 1
Participant perspectives on the impact of CHARISMA

Similar articles

Cited by

References

    1. Malow R, Ziskind D, Jones D. Use of female controlled microbicidal products for HIV risk reduction. AIDS Care. 2000;12(5):581–588. doi: 10.1080/095401200750003761. - DOI - PubMed
    1. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect. 2005;81(3):193–200. doi: 10.1136/sti.2003.007153. - DOI - PMC - PubMed
    1. Stein ZA, Myer L, Susser M. The design of prophylactic trials for HIV: the case of microbicides. Epidemiology, 2003; 14(1):80–83; discussion 83–84. 10.1097/00001648-200301000-00018. - PubMed
    1. Montgomery ET, van der Straten A, Stadler J, Hartmann M, Magazi B, Mathebula F, Laborde N, Soto-Torres L. Male partner influence on women’s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of “understanding”. AIDS Behav. 2015;19(5):784–793. doi: 10.1007/s10461-014-0950-5. - DOI - PMC - PubMed
    1. Lanham M, Wilcher R, Montgomery ET, Pool R, Schuler S, Lenzi R, Friedland B. Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc. 2014;17:19159. doi: 10.7448/IAS.17.3.19159. - DOI - PMC - PubMed

Publication types